An autoinflammatory CDC42 variant M45L demonstrates the mechanism of pyrin inflammasome activation

View at publisher
Authors: Shouya Feng, Thomas Reygaerts, Klara Kong, Matthew C Wierzbowski, Dhanya Lakshmi Narayanan, Paul J. Baker, Imogen Bishop, Maria Zyulina, Katherine Rosevear, Madeline L. Cleveland, Tim Hewitt, T. Daniel Andrews
+9 more Davide Randazzo, Peter Steinbach, Jae Jin Chae, Hyeonji Kim, Daniel L. Kastner, William D Renton, Samar Ojaimi, Wonyong Lee, Seth L. Masters
Cited by: 4
References: 63

Abstract

CDC42 is an evolutionarily conserved guanosine triphosphatase (GTPase) regulating critical cellular and immune processes. Variants in CDC42 therefore cause a spectrum of developmental phenotypes, including hematological and immunological symptoms. Here, we identify a previously unrecognized autoinflammatory condition caused by CDC42 Met45→Leu(M45L) . We confirm the pathogenicity of CDC42 M45L given that it promotes pyrin inflammasome activation, consistent with highly elevated circulating interleukin-18 (IL-18) in all affected individuals. Coimmunoprecipitation demonstrates that CDC42 interacts with the PYD and B30.2 domains of pyrin. The B30.2 interaction is greatly enhanced by CDC42 M45L . Models show that CDC42 methionine-45 sits in a hydrophobic cleft of the pyrin B30.2 domain, and substitution with a negatively charged residue prevents colocalization between CDC42 and pyrin. This study supports a model whereby CDC42 nucleates pyrin via the B30.2 domain, after which a threshold is reached to liberate the PYD for inflammasome activation. Blocking the inflammasome-associated cytokine IL-1 was therapeutically effective when tested against this autoinflammatory CDC42 M45L endotype.

Fields of Study & Subjects

Inflammasome and immune disorders Toxoplasma gondii Research Studies Osteomyelitis and Bone Disorders Research

Publication details

Journal / source
Science Immunology
Publisher
American Association for the Advancement of Science (AAAS)
Volume
11
Issue
122
Pages
eadz8733–eadz8733
Publication date
7 August 2026
Language
EN